Heart disease experts are hailing the results of a clinical trial showed a strongly positive performance by a drug that ...

AstraZeneca’s new cholesterol pill is showing promise, while the FTC urged a potential buyer of 23andMe to protect user data.

Amgen is a leading biopharmaceutical company that develops innovative medicines in areas with significant unmet needs. Read ...

After a previously reported positive phase 2 trial in systemic lupus erythematosus (SLE), the TYK2 inhibitor deucravacitinib ...

Oral semaglutide, already approved for type 2 diabetes, led to a reduction in CV events in patients with established ...

A federal judge has thrown out Amgen’s lawsuit against the state board empowered to set price ceilings on prescription drugs ...

Four of the 30 stocks that make up the Dow Jones Industrial Average represent the healthcare sector. Within that group, ...

Options trading presents higher risks and potential rewards. Astute traders manage these risks by continually educating ...

Amgen (AMGN) concluded the recent trading session at $311.55, signifying a +1.5% move from its prior day's close.

In the coming two weeks, the FDA is expected to announce three big decisions, including one for a dry eye disease therapy.

TD Cowen analyst Yaron Werber maintained a Buy rating on Amgen (AMGN – Research Report) today and set a price target of $389.00. The company’s ...